VuBru, I don’t know either if DCVax-L will be approved by any of the regulatory authorities on a tissue-agnostic basis. But for the sake of solid tumor cancer patients around the world, I hope this will happen soon.
The excellent safety profile and the non-toxicity of DCVax-L bodes well, and the fact that it proved clinically meaningful and significant efficacy in treating GBM patients, which is 1 of the hardest to treat solid tumor cancers, bodes well also.
I asked ChatGPT a short simple question, and I received a concise and direct reply:
News 
Market Data 
Discover 
